×
QQQ   283.54 (-3.05%)
AAPL   137.44 (-2.98%)
MSFT   256.48 (-3.17%)
META   160.68 (-5.20%)
GOOGL   2,240.15 (-3.30%)
AMZN   107.40 (-5.14%)
TSLA   697.99 (-5.00%)
NVDA   159.82 (-5.26%)
NIO   22.36 (-2.57%)
BABA   116.76 (-1.66%)
AMD   80.78 (-6.24%)
MU   57.86 (-1.57%)
CGC   3.61 (-4.75%)
T   20.61 (-0.82%)
GE   65.88 (-1.24%)
F   11.81 (-1.91%)
DIS   95.92 (-0.71%)
AMC   13.38 (-5.31%)
PFE   50.66 (-2.35%)
PYPL   71.82 (-5.43%)
NFLX   179.60 (-5.04%)
QQQ   283.54 (-3.05%)
AAPL   137.44 (-2.98%)
MSFT   256.48 (-3.17%)
META   160.68 (-5.20%)
GOOGL   2,240.15 (-3.30%)
AMZN   107.40 (-5.14%)
TSLA   697.99 (-5.00%)
NVDA   159.82 (-5.26%)
NIO   22.36 (-2.57%)
BABA   116.76 (-1.66%)
AMD   80.78 (-6.24%)
MU   57.86 (-1.57%)
CGC   3.61 (-4.75%)
T   20.61 (-0.82%)
GE   65.88 (-1.24%)
F   11.81 (-1.91%)
DIS   95.92 (-0.71%)
AMC   13.38 (-5.31%)
PFE   50.66 (-2.35%)
PYPL   71.82 (-5.43%)
NFLX   179.60 (-5.04%)
QQQ   283.54 (-3.05%)
AAPL   137.44 (-2.98%)
MSFT   256.48 (-3.17%)
META   160.68 (-5.20%)
GOOGL   2,240.15 (-3.30%)
AMZN   107.40 (-5.14%)
TSLA   697.99 (-5.00%)
NVDA   159.82 (-5.26%)
NIO   22.36 (-2.57%)
BABA   116.76 (-1.66%)
AMD   80.78 (-6.24%)
MU   57.86 (-1.57%)
CGC   3.61 (-4.75%)
T   20.61 (-0.82%)
GE   65.88 (-1.24%)
F   11.81 (-1.91%)
DIS   95.92 (-0.71%)
AMC   13.38 (-5.31%)
PFE   50.66 (-2.35%)
PYPL   71.82 (-5.43%)
NFLX   179.60 (-5.04%)
QQQ   283.54 (-3.05%)
AAPL   137.44 (-2.98%)
MSFT   256.48 (-3.17%)
META   160.68 (-5.20%)
GOOGL   2,240.15 (-3.30%)
AMZN   107.40 (-5.14%)
TSLA   697.99 (-5.00%)
NVDA   159.82 (-5.26%)
NIO   22.36 (-2.57%)
BABA   116.76 (-1.66%)
AMD   80.78 (-6.24%)
MU   57.86 (-1.57%)
CGC   3.61 (-4.75%)
T   20.61 (-0.82%)
GE   65.88 (-1.24%)
F   11.81 (-1.91%)
DIS   95.92 (-0.71%)
AMC   13.38 (-5.31%)
PFE   50.66 (-2.35%)
PYPL   71.82 (-5.43%)
NFLX   179.60 (-5.04%)
TSE:GUD

Knight Therapeutics Stock Forecast, Price & News

C$5.42
+0.09 (+1.69%)
(As of 06/28/2022 12:00 AM ET)
Add
Compare
Today's Range
C$5.33
C$5.42
50-Day Range
C$5.07
C$5.46
52-Week Range
C$5.01
C$5.74
Volume
141,847 shs
Average Volume
210,378 shs
Market Capitalization
C$624.87 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
C$7.00
30 days | 90 days | 365 days | Advanced Chart

Receive GUD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Knight Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

GUD Stock Forecast (MarketRank)

Overall MarketRank

2.14 out of 5 stars

Analyst Opinion: 3.4Community Rank: 5.0Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -
Knight Therapeutics logo

About Knight Therapeutics (TSE:GUD)

Knight Therapeutics Inc., a specialty pharmaceutical company, develops, acquires, in-licenses, out-licenses, markets, and distributes pharmaceutical and consumer health products, and medical devices in Canada, Latin America, and internationally. It offers Nerlynx for extended adjuvant breast cancer and metastatic breast cancer; Tafasitamab for relapsed or refractory diffuse large B-cell lymphoma; Pemigatinib to treat metastatic cholangiocarcinoma; Trelstar for advanced prostate cancer and for pain associated with endometriosis; Vidaza for myelodysplastic syndrome; Abraxane for metastatic pancreatic adenocarcinoma; Halaven for metastatic breast cancer and doft tissue sarcoma; and Lenvima for differentiated thyroid cancer, advanced renal cell cancer, and unresectable hepatocellular carcinoma. The company also provides Ladevina for multiple myeloma, myelodysplastic syndrome, mantle cell lymphoma, and follicular lymphoma; Zyvalix for metastatic prostate cancer; Karfib for relapsed or refractory multiple myeloma; Leprid for advanced prostate cancer; Rembre for chronic myeloid leukemia; Ambisome and Cresemba for fungal infection; Impavido for leishmaniasis; Exelon for mild to moderately severe dementia; and Ibsrela for the treatment of irritable bowel syndrome with constipation. In addition, it offers Salofalk for ulcerative colitis; Ursofalk to treat biliary cirrhosis; Imvexxy for moderate to severe dyspareunia; Bijuva for moderate to severe vasomotor symptoms associated with menopause in women with intact uteri; Fibridoner to treat idiopathic pulmonary fibrosis; Toliscrin DPI for pseudomonas aeruginosa lung infection in patients with cystic fibrosis; Toliscrin 1-2 for severe acute or resistant chronic infections; and Tobradosa Haler for chronic lung infections. Further, the company finances other life science companies; and invests in life sciences venture capital funds. Knight Therapeutics Inc. was incorporated in 2013 and is headquartered in Montreal, Canada.

GUD Stock News Headlines

Insiders are buying as Knight Therapeutics consolidates
Stocks in play: Knight Therapeutics Inc
See More Headlines

Industry, Sector and Symbol

Industry
Drug Manufacturers - Specialty & Generic
Sub-Industry
N/A
Sector
Medical
CIK
N/A
Fax
N/A
Employees
660
Year Founded
N/A

Company Calendar

Last Earnings
5/12/2022
Today
6/28/2022
Next Earnings (Estimated)
8/12/2022

Price Target and Rating

Average Stock Price Forecast
C$7.00
High Stock Price Forecast
C$7.50
Low Stock Price Forecast
C$5.30
Forecasted Upside/Downside
+29.2%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.83333333333333
Research Coverage
6 Analysts

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
C$261.22 million
Cash Flow
C$1.51 per share
Book Value
C$7.12 per share

Miscellaneous

Free Float
N/A
Market Cap
C$624.87 million
Optionable
Not Optionable
Beta
N/A














Knight Therapeutics Frequently Asked Questions

Should I buy or sell Knight Therapeutics stock right now?

6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Knight Therapeutics in the last year. There are currently 1 hold rating and 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" Knight Therapeutics stock.
View analyst ratings for Knight Therapeutics
or view top-rated stocks.

What is Knight Therapeutics' stock price forecast for 2022?

6 Wall Street analysts have issued 12-month price objectives for Knight Therapeutics' shares. Their GUD stock forecasts range from C$5.30 to C$7.50. On average, they predict Knight Therapeutics' stock price to reach C$7.00 in the next twelve months. This suggests a possible upside of 29.2% from the stock's current price.
View analysts' price targets for Knight Therapeutics
or view top-rated stocks among Wall Street analysts.

How has Knight Therapeutics' stock price performed in 2022?

Knight Therapeutics' stock was trading at C$5.30 at the beginning of the year. Since then, GUD stock has increased by 2.3% and is now trading at C$5.42.
View the best growth stocks for 2022 here
.

When is Knight Therapeutics' next earnings date?

Knight Therapeutics is scheduled to release its next quarterly earnings announcement on Friday, August 12th 2022.
View our earnings forecast for Knight Therapeutics
.

How were Knight Therapeutics' earnings last quarter?

Knight Therapeutics Inc. (TSE:GUD) announced its earnings results on Thursday, May, 12th. The company reported ($0.02) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.04) by $0.02. The company had revenue of $63.81 million for the quarter, compared to the consensus estimate of $52.80 million.
View Knight Therapeutics' earnings history
.

Who are Knight Therapeutics' key executives?

Knight Therapeutics' management team includes the following people:
  • Mr. Jonathan Ross Goodman B.A., BA, L.L.B., LLB, M.B.A., MBA, Exec. Chairman (Age 53, Pay $455.25k)
  • Ms. Samira Sakhia BCom, CA, CPA, MBA, Pres, CEO & Director (Age 54, Pay $691.66k)
  • Mr. Arvind Utchanah, Chief Financial Officer
  • Ms. Amal Khouri M.B.A., Chief Bus. Officer
  • Mr. Jeff Martens, Global VP Commercial
  • Mr. Leopoldo Bosano, Vice-Pres of Manufacturing & Operations
  • Ms. Daniela Marino, Global VP of Legal & Compliance
  • Ms. Susan Caroline Emblem, Global VP of HR
  • Ms. Jody Engel, Sr. Director of Bus. Devel.

What other stocks do shareholders of Knight Therapeutics own?

What is Knight Therapeutics' stock symbol?

Knight Therapeutics trades on the Toronto Stock Exchange (TSX) under the ticker symbol "GUD."

How do I buy shares of Knight Therapeutics?

Shares of GUD and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.
Compare Top Brokerages Here.

What is Knight Therapeutics' stock price today?

One share of GUD stock can currently be purchased for approximately C$5.42.

How much money does Knight Therapeutics make?

Knight Therapeutics (TSE:GUD) has a market capitalization of C$624.87 million and generates C$261.22 million in revenue each year.

How many employees does Knight Therapeutics have?

Knight Therapeutics employs 660 workers across the globe.

How can I contact Knight Therapeutics?

The official website for Knight Therapeutics is www.gud-knight.com. The company can be reached via phone at 514-484-4483.

This page (TSE:GUD) was last updated on 6/28/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.